Chardan analyst Keay Nakae lowered the firm’s price target on SAB Biotherapeutics (SABS) to $20 from $25 and keeps a Buy rating on the shares after the company reported its Q4 and full year results. The company remains on track to initiate the Phase 2 SAFEGUARD clinical study to evaluate SAB-142, notes the analyst, who lowered the firm’s price target to reflect a higher projected future share count as modeled future capital raises, including one in Q2, are expected to be more dilutive due to the current share price.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SABS: